Scholarlink

Background <p>To evaluate the association between triple therapy (hydroxychloroquine sulfate, aspirin, and enoxaparin sodium) and pregnancy outcomes in patients with undifferentiated connective tissue disease (UCTD)-related recurrent miscarriage (RM).</p> Methods <p>This retrospective cohort study included 135 pregnant women with recurrent miscarriage treated at a single center between January 2021 and August 2024. Patients were assigned to three groups according to treatment regimen: control group 1 (progesterone + enoxaparin sodium), control group 2 (aspirin + enoxaparin sodium), and the triple therapy group (hydroxychloroquine + aspirin + enoxaparin sodium). The primary outcome was live birth (≥ 28 weeks). Multivariable logistic regression analysis was performed to adjust for baseline differences using a parsimonious model including treatment group, maternal age, and gestational age at last pregnancy loss.</p> Results <p>In unadjusted analysis, the triple therapy group had a significantly higher live birth rate (95.6%) than the control group 1 (80.0%) and control group 2 (77.8%) (<i>P</i> = 0.028). The higher live birth rate was mainly driven by increased fetal survival, despite a numerically higher preterm birth rate. After adjustment for baseline differences, the association between triple therapy and live birth was attenuated and did not reach statistical significance, although the direction of effect remained consistent with the unadjusted analysis. No significant difference was observed between control group 2 and control group 1 in the adjusted analysis. Gestational age at last pregnancy loss was significantly associated with live birth, whereas maternal age was not. No increase in adverse reactions or differences in neonatal outcomes was observed among the groups.</p> Conclusion <p>Triple therapy with hydroxychloroquine, aspirin, and enoxaparin sodium was associated with improved live birth outcomes in patients with UCTD-related recurrent miscarriage. However, this association was attenuated and did not remain statistically significant after adjustment for baseline differences. Given the retrospective design and limited sample size, further prospective studies are required to confirm these findings.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effects of hydroxychloroquine sulfate combined with aspirin and enoxaparin sodium therapy on perinatal outcomes in patients with undifferentiated connective tissue disease-related recurrent miscarriage: a retrospective clinical study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月27日

查看全文
  • Liu-Cheng Pei,
  • Ting Wang,
  • Ya-Juan Guo,
  • Qiu-Ling Yang,
  • Wen-Di Liu,
  • Cheng-Wei Jiang,
  • Peng-Chao Yan,
  • Xue-Jie Li,
  • Chun-Jun Wang

摘要

Background

To evaluate the association between triple therapy (hydroxychloroquine sulfate, aspirin, and enoxaparin sodium) and pregnancy outcomes in patients with undifferentiated connective tissue disease (UCTD)-related recurrent miscarriage (RM).

Methods

This retrospective cohort study included 135 pregnant women with recurrent miscarriage treated at a single center between January 2021 and August 2024. Patients were assigned to three groups according to treatment regimen: control group 1 (progesterone + enoxaparin sodium), control group 2 (aspirin + enoxaparin sodium), and the triple therapy group (hydroxychloroquine + aspirin + enoxaparin sodium). The primary outcome was live birth (≥ 28 weeks). Multivariable logistic regression analysis was performed to adjust for baseline differences using a parsimonious model including treatment group, maternal age, and gestational age at last pregnancy loss.

Results

In unadjusted analysis, the triple therapy group had a significantly higher live birth rate (95.6%) than the control group 1 (80.0%) and control group 2 (77.8%) (P = 0.028). The higher live birth rate was mainly driven by increased fetal survival, despite a numerically higher preterm birth rate. After adjustment for baseline differences, the association between triple therapy and live birth was attenuated and did not reach statistical significance, although the direction of effect remained consistent with the unadjusted analysis. No significant difference was observed between control group 2 and control group 1 in the adjusted analysis. Gestational age at last pregnancy loss was significantly associated with live birth, whereas maternal age was not. No increase in adverse reactions or differences in neonatal outcomes was observed among the groups.

Conclusion

Triple therapy with hydroxychloroquine, aspirin, and enoxaparin sodium was associated with improved live birth outcomes in patients with UCTD-related recurrent miscarriage. However, this association was attenuated and did not remain statistically significant after adjustment for baseline differences. Given the retrospective design and limited sample size, further prospective studies are required to confirm these findings.